TUDRIQEV (vusolimogene oderparepvec-wtpg) — Full data
2026
We have closed enrollment in the ARTACUS trial and are planning a publication of the data in 2026.Source filing
REPL biotech catalysts & pipeline
REPLIMUNE GROUP INC · Data as of 2026-09-08
Upcoming catalysts
RP2 (sturlimgene erparepvec) — Topline data
Late 2026
The protocol was amended to include RP2 as monotherapy with data planned by the end of 2026.Source filing
RP2 (sturlimgene erparepvec) — Interim data
Q1 2027
In January 2026 we announced the Phase 2/3 transition is expected to occur in the first quarter of 2027.Source filing
RP2 (sturlimgene erparepvec) — Regulatory decision
Q1 2027
Phase 2/3 transition is expected in Q1 2027.Source filing
RP1 + Nivolumab — Interim data
2H 2027
• Interim OS analysis planned for 2H 2027Source filing
vusolimogene oderparepvec — Interim data
H2 2027
We are also planning for an interim overall survival, or OS, analysis in the second half of 2027.Source filing
TUDRIQEV (vusolimogene oderparepvec-wtpg) — Topline data
2030
IGNYTE-3 randomized confirmatory trial ongoing with OS data expected in 2030Source filing
vusolimogene oderparepvec — Topline data
2030
The primary endpoint, expected to readout in 2030, is overall survival, and key secondary endpoints are progression free survival and overall response rate.Source filing